- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02419898
Oxfordshire Women and Their Children's Health (OxWATCH)
Oxfordshire Women and Their Children's Health- A Feasibility Study
The aim of this feasibility study is to test recruitment of participants into Phase 1 of the study and then the re-recruitment and retention of participants in Phase 2 of the study. The investigators will also be assessing the acceptability of recruitment strategy and data collection to participants.
The effect of pre-pregnancy factors (biophysical, genetic, socioeconomic, behavioural and psychological) on obstetric, cardiovascular, socioeconomic, behavioural and psychological outcomes will all be examined.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
The aim of this study is to recruit 300 women. The investigators anticipate that a subset of recruits will become pregnant during the pilot study.
This is a feasibility study with two phases:
- Phase 1: A detailed characterisation of nulliparous women who have an address in Oxfordshire or work in Oxfordshire
- Phase 2: Detailed assessment of events during and immediately after a first viable pregnancy.
During the Phase 1 visit:
- Participation is explained by a research nurse/midwife, any questions are answered and women, who agree, sign the consent form.
- A questionnaire covering medical and family history, socioeconomic information, behavioural factors and psychological measures will be completed.
- Baseline anthropometry - height, weight, hip/ waist ratio, USS measurement of fat (thigh and abdomen), bioimpedence.
- Cardiovascular - pulse and BP (peripheral / central), arterial stiffness, echocardiogram, carotid imaging and endothelial function (endo-check) tests are completed.
- Fasting venous blood sample (maximum 40 mls) including whole blood for maternal DNA.
- Urine sample
- Salivette
Once a participant has become pregnant she is eligible to enter phase 2 of the study. Phase 2 involves 6 further visits at 7, 11-13, 18-20, 28, 34 weeks gestation and 3 months post-delivery. During these visits repeated measurements of the above investigations will be carried out.
In addition, there will be a fetal ultrasound at 7 and 28 weeks and questionnaires at 7, 28 and 3 months post-delivery. An acceptability questionnaire will also be given to participants following completion of the study.
The end of the feasibility study will be the date of the final phase 2 visit of the last participant becoming pregnant during the feasibility study.
By collecting the above data the investigators anticipate recording and reporting longitudinal data in relation to the following:
•Incidence of obstetric complications
The incidence of pre-eclampsia, gestational diabetes, pregnancy induced hypertension, antenatal and postnatal depression and preterm birth.
•Longitudinal variation in cardiovascular parameters
Changes in longitudinal measures of blood pressure, carotid intima media thickness, pulse wave velocity, cardiac structure and function and endothelial function from pre-conception until 34 weeks gestation.
•Longitudinal changes in socioeconomic factors
By use of a questionnaire at pre-conception, 7 weeks gestation and 28 weeks gestation we will record employment and relationship status.
•Longitudinal changes in behavioural factors
By use of a questionnaire at pre-conception, 7 weeks gestation and 28 weeks gestation the investigators will record diet, weight control and perception, exercise, smoking, alcohol use and drug use.
•Longitudinal changes in psychological factors
By use of a questionnaire at pre-conception, 7 weeks gestation and 28 weeks gestation the investigators will record levels of anxiety, depression and quality of life and perceived health status.
•Longitudinal changes in the health status of participant and their family
By use of a questionnaire at pre-conception the investigators will record the participants' medical and family history, reproductive and sexual history and pain perception. At 7 weeks gestation and 28 weeks gestation the questionnaire will enquire about any changes or additions to the participants' medical and family history as well as reproductive and sexual health and pain perception.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
-
Oxford, Verenigd Koninkrijk, OX39DU
- Werving
- The Nuffield Department of Obstetrics and Gynaecology
-
Contact:
- Ingrid Granne
- Telefoonnummer: 01865 740887
- E-mail: ingrid.granne@obs-gyn.ox.ac.uk
-
Contact:
- Sian Harrison
- Telefoonnummer: 01865 289358
- E-mail: sian.harrison@phc.ox.ac.uk
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study
- Participant is female, aged 18-40 years
- Participant is not pregnant
- Participant lives or works in Oxfordshire
Exclusion Criteria:
- A previous live birth or still birth after 24 weeks gestation
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Feasibility Study
Nulliparous women of reproductive age (18-40 years), who are not pregnant but could have a planned or unplanned pregnancy during the duration of the study.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Recruitment feasibility
Tijdsspanne: 2 years
|
This will be measured by the number of participants recruited into Phase 1 (pre-pregnancy) and Phase 2 (pregnancy) of the study.
The investigators intend to recruit 300 participants into Phase 1 and 100 participants into Phase 2.
|
2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Levend geboortecijfer
Tijdsspanne: 2 jaar
|
2 jaar
|
|
|
The retention of participants in Phase 2
Tijdsspanne: 2 years
|
The investigators aim to retain 90% of participants recruited into Phase 2 from 7 weeks gestation until delivery.
|
2 years
|
|
Incidence of pregnancy within 12 months of recruitment.
Tijdsspanne: 2 years in total, 12 month for each recruit
|
2 years in total, 12 month for each recruit
|
|
|
Incidence of miscarriage and ectopic pregnancy in Phase 2 participants
Tijdsspanne: 2 years
|
2 years
|
|
|
Incidence of loss to follow-up
Tijdsspanne: 2 years
|
2 years
|
|
|
Proportion of participants who provide full data at baseline and throughout pregnancy
Tijdsspanne: 2 years
|
2 years
|
|
|
Acceptability of the recruitment strategy to participants
Tijdsspanne: 2 years
|
At the end of a participant's involvement in the study the participant will be asked to complete an anonymous, validated acceptability questionnaire.
It is anticipated that this will provide insight into why participants took part, the acceptability of the recruitment strategy, the participant's reactions to research participation and how acceptable the participant found study requirements and assessments.
|
2 years
|
|
Acceptability of the data collection procedures to participants.
Tijdsspanne: 2 years
|
At the end of a participant's involvement in the study the participant will be asked to complete an anonymous, validated acceptability questionnaire.
It is anticipated that this will provide insight into why participants took part, the acceptability of the recruitment strategy, the participant's reactions to research participation and how acceptable the participant found study requirements and assessments.
|
2 years
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Ingrid Granne, University of Oxford
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 12/SC/0492
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .